Hydralazine Amdipharm Uk Limited

Hydralazine Amdipharm Uk Limited is a pharmaceutical product containing the active ingredient hydralazine hydrochloride, supplied in oral dosage form. It is a direct‑acting vasodilator classified as an antihypertensive, marketed in the European Union. The medication is prescription‑only and is used under medical supervision for conditions involving elevated blood pressure and certain types of heart failure. It is manufactured by Amdipharm UK Limited and complies with EU pharmaceutical standards.

Hydralazine Amdipharm Uk Limited is indicated for the management of specific cardiovascular conditions where reduction of vascular resistance is desired.

- Essential (primary) hypertension, where peripheral vascular resistance contributes to elevated blood pressure. - Congestive heart failure, particularly in patients who require afterload reduction and may be combined with diuretics or beta‑blockers. - Hypertensive emergencies or severe uncontrolled hypertension as an adjunct to faster‑acting agents. - Pregnancy‑related hypertension (e.g., pre‑eclampsia) where other antihypertensives are contraindicated, reflecting its Category B classification. - Off‑label use in certain renal vascular disorders under specialist supervision, based on individual risk‑benefit assessment.

Hydralazine may cause a range of adverse reactions, varying from mild to potentially serious.

Common: - Headache: mild to moderate head pain that may be throbbing or pressure‑like, typically appearing within hours of dosing and often resolving without intervention. - Tachycardia: increase in heart rate, sometimes accompanied by palpitations, usually occurring shortly after the dose and may require monitoring. - Flushing: warm sensation and reddening of the skin, especially on the face, neck, and upper chest, often transient but occasionally uncomfortable.

Serious: - Drug‑induced lupus erythematosus: an immune‑mediated syndrome characterized by joint pain, fever, rash, and positive antinuclear antibodies, which usually resolves after discontinuation. - Severe hypotension: a marked drop in blood pressure that can lead to dizziness, syncope, or organ hypoperfusion, requiring immediate medical attention. - Agranulocytosis: a dangerous reduction in neutrophil count, markedly increasing the risk of bacterial infections and necessitating prompt laboratory monitoring.

When prescribing Hydralazine, clinicians should consider several precautionary measures to ensure safe use.

- Pregnancy: classified as Category B, but blood pressure should be closely monitored and alternative agents considered if risk outweighs benefit. - Hepatic impairment: dose adjustment may be necessary because the drug is metabolized in the liver. - Renal impairment: use with caution; accumulation can occur in severe renal dysfunction. - Concurrent beta‑blocker therapy: may mask tachycardia, requiring careful heart‑rate monitoring. - Lupus‑like syndrome: patients with a history of autoimmune disease should be observed for joint pain or rash. - Abrupt discontinuation: sudden stop can cause rebound hypertension; tapering is recommended. - Coronary artery disease: may precipitate myocardial ischemia due to reflex tachycardia; monitor chest pain.

Hydralazine can interact with several medicines, influencing its efficacy or safety profile.

Avoid: - Other potent vasodilators (e.g., nitroglycerin, minoxidil, sodium nitroprusside): combined use may cause excessive hypotension and reflex tachycardia. - Direct sympathomimetic agents (e.g., epinephrine, norepinephrine): may counteract hydralazine’s vasodilatory effect and increase cardiovascular stress.

Use with caution: - Beta‑blockers: can mask hydralazine‑induced tachycardia, requiring close heart‑rate monitoring. - ACE inhibitors or angiotensin‑receptor blockers: additive blood‑pressure lowering effect may increase risk of hypotension. - Diuretics: may enhance volume depletion and orthostatic hypotension; monitor electrolytes. - Immunosuppressive or lupus‑inducing drugs (e.g., procainamide, isoniazid): may raise the likelihood of drug‑induced lupus erythematosus.